Len Post

Len Post, Ph.D. an advisor to BridgeBio and also serves as the Chief Scientific Officer of Vivace Therapeutics and Virtuoso Therapeutics. Dr. Post served in various positions at BioMarin, including Chief Scientific Officer, during which time he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. He is also currently an advisor to Canaan Partners and sits on the Board of Directors of UniQure.